Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avastin and chemotherapy followed by KRAS-stratified maintenance treatment in first-line metastatic colorectal cancer
2010-019815-40Phase 3Completed
- Sponsor
- Skåne University Hospital
- Start
- Mar 2011
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of bevacizumab, erlotinib and capecitabine in metastatic colorectal adenocarcinoma (mCRC) (3 arms), sponsored by Skåne University Hospital. Primary endpoint: Progression-free survival rate at 3 months in KRAS wild-type cohort. Started Mar 2011; status: completed.
02
Drugs
bevacizumaberlotinibcapecitabine
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2010-019815-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019815-40.